Abstract 2017P
Background
Small cell lung cancer (SCLC) is one of the most lethal forms of lung cancer, with a 5-year survival rate of approximately 7%. SCLC has been divided into limited stage (LS) and extensive stage (ES). For ES-SCLC the use of immunotherapy (IO) has been introduced in combination with platinum-based chemotherapy (CT), prolonging the overall survival of patients. However, only a small fraction of patients experience a durable clinical benefit from this approach, with no selection criteria able to predict clinical outcome. Here we hypothesize that different mutational profiles could be associated to clinical outcome of patients treated with CT-IO with respect to CT alone.
Methods
A case series of 88 ES-SCLC patients was enrolled. Tumor tissues of patients were analysed with a next-generation sequencing-based assay (Foundation One CDx), analysing 324 genes, selected gene rearrangements, microsatellite instability (MSI) and tumor mutational burden (TMB). Statistical analyses have been performed to study the correlation among clinical characteristics, mutational profiles and clinical outcome has been performed.
Results
For patients with available clinical information, 36 were treated with CT-IO and 50 with CT alone. The 65% of patients were male, and the 35% were female, median age was 71 (range 50-86) years old. The 36.2% of patients were former smokers whereas 53.75% were current smokers, while smoking habits were not available for 16 patients. The most frequently mutated genes were TP53 (98%), RB1 (80%), MLL2 (35%), NOTCH3 (16.2%), MLL (12.5%), RICTOR (8.8%), CDKN2A/B (7.3%), APC (7.3%), MYC (6.3%) and MYCL1 (6.3%). No rearrangements were detected in any patient. With regard to TMB, 25% of patients had low TMB (<6 mut/Mb), 65% of patients had intermediate TMB (6>20 mut/Mb), and 10% of patients had high TMB (>20 mut/Mb). MSI data was available for 67 patients, and all but one patients were stable. Survival analyses and correlation of clinical outcome with mutational profiles are still ongoing.
Conclusions
Our results suggest that a comprehensive genomic profile could help to predict clinical outcome of ES-SCLC patients treated with CT-IO.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1866P - Unmasking the extent of hidden sexual distress in young breast cancer survivors
Presenter: Zeineb Naimi
Session: Poster session 05
1867P - A cross-sectional examination of information disclosure and health literacy amongst patients with lymphoma
Presenter: Steve Kalloger
Session: Poster session 05
1868P - Challenges for shared decision making in incurable cancer, with a focus on health literacy
Presenter: Chloe Holden
Session: Poster session 05
1871P - The PainRELife ecosystem: A new aid for improving clinical care and shared decision-making in breast cancer patients with chronic pain
Presenter: Marianna Masiero
Session: Poster session 05
1872P - Financial distress of a cancer disease in Germany: A new patient reported outcome measure (PROM) and first results from a bi-centered cross-sectional analysis
Presenter: Sophie Pauge
Session: Poster session 05
1873P - Patients with myeloproliferative neoplasms and self-care behaviours: Preliminary data of a cross-sectional study
Presenter: Valentina Biagioli
Session: Poster session 05
1874P - Beliefs about chemotherapy in Tunisian patients newly diagnosed with cancer
Presenter: Hadhemi Ayadi
Session: Poster session 05
1875P - Behind the use of ChatGPT for oncological purposes: Fears and challenges
Presenter: Ilaria Durosini
Session: Poster session 05
1876P - Cancer stigma: How Tunisian patients perceive their cancer
Presenter: sofiene Fendri
Session: Poster session 05